Small-animal model to measure efficacy and immunogenicity of Shigella vaccine strains
- PMID: 1937767
- PMCID: PMC258999
- DOI: 10.1128/iai.59.11.4075-4083.1991
Small-animal model to measure efficacy and immunogenicity of Shigella vaccine strains
Abstract
The development of a small-animal model to test the protective efficacy and immunogenicity of a vaccine strain against shigellosis would greatly facilitate the evaluation of potential vaccine candidates. In guinea pigs, the ability of shigellae to invade and multiply within the corneal epithelium, causing keratoconjunctivitis, closely mimics the invasion process in the intestinal epithelium (B. Sereny, Acta Microbiol. Acad. Sci. Hung. 4:367-376, 1957). The serum response of animals recovering from a Shigella keratoconjunctival infection was determined and found to be consistent with that shown by convalescent humans and primates. This model was used to test the efficacy of two vaccine candidates, and the immune response of the guinea pigs to the vaccine strains was examined. Both vaccine strains demonstrated significant protection against challenge by homologous virulent Shigella strains, and the results were comparable with results obtained in trials with monkeys. The guinea pig model also provides a rapid and inexpensive means of evaluating different immunization regimens as well as of testing other variables such as length of protection against disease.
Similar articles
-
Immunogenicity of multivalent Shigella-ETEC candidate vaccine strains in a guinea pig model.Vaccine. 2006 May 1;24(18):3727-34. doi: 10.1016/j.vaccine.2005.07.013. Epub 2005 Jul 22. Vaccine. 2006. PMID: 16169130
-
Further characterization of delta aroA delta virG Shigella flexneri 2a strain CVD 1203 as a mucosal Shigella vaccine and as a live-vector vaccine for delivering antigens of enterotoxigenic Escherichia coli.Infect Immun. 1996 Jan;64(1):23-7. doi: 10.1128/iai.64.1.23-27.1996. Infect Immun. 1996. PMID: 8557344 Free PMC article.
-
Attenuated Shigella flexneri 2a Delta guaBA strain CVD 1204 expressing enterotoxigenic Escherichia coli (ETEC) CS2 and CS3 fimbriae as a live mucosal vaccine against Shigella and ETEC infection.Infect Immun. 2001 May;69(5):3150-8. doi: 10.1128/IAI.69.5.3150-3158.2001. Infect Immun. 2001. PMID: 11292735 Free PMC article.
-
Development of an auxotrophic oral live Shigella flexneri vaccine.Vaccine. 1988 Apr;6(2):146-50. doi: 10.1016/s0264-410x(88)80018-5. Vaccine. 1988. PMID: 2838986 Review.
-
Live attenuated Shigella flexneri mutants as vaccine candidates against shigellosis and vectors for antigen delivery.Biologicals. 1995 Jun;23(2):125-34. doi: 10.1006/biol.1995.0023. Biologicals. 1995. PMID: 7546655 Review.
Cited by
-
Development of the Shigella flexneri 2a, 3a, 6, and S. sonnei artificial Invaplex (InvaplexAR) vaccines.mSphere. 2023 Aug 24;8(4):e0007323. doi: 10.1128/msphere.00073-23. Epub 2023 Jun 30. mSphere. 2023. PMID: 37389412 Free PMC article.
-
The Shigella Vaccines Pipeline.Vaccines (Basel). 2022 Aug 24;10(9):1376. doi: 10.3390/vaccines10091376. Vaccines (Basel). 2022. PMID: 36146457 Free PMC article. Review.
-
From Concept to Clinical Product: A Brief History of the Novel Shigella Invaplex Vaccine's Refinement and Evolution.Vaccines (Basel). 2022 Apr 1;10(4):548. doi: 10.3390/vaccines10040548. Vaccines (Basel). 2022. PMID: 35455297 Free PMC article. Review.
-
Recent Progress in Shigella and Burkholderia pseudomallei Vaccines.Pathogens. 2021 Oct 20;10(11):1353. doi: 10.3390/pathogens10111353. Pathogens. 2021. PMID: 34832508 Free PMC article. Review.
-
Rationalizing the design of a broad coverage Shigella vaccine based on evaluation of immunological cross-reactivity among S. flexneri serotypes.PLoS Negl Trop Dis. 2021 Oct 13;15(10):e0009826. doi: 10.1371/journal.pntd.0009826. eCollection 2021 Oct. PLoS Negl Trop Dis. 2021. PMID: 34644291 Free PMC article.
References
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources